Patents by Inventor Philippe Denoel
Philippe Denoel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140294935Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.Type: ApplicationFiled: May 12, 2014Publication date: October 2, 2014Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, George Thiry, Joelle Thonnard, Pierre Voet
-
Publication number: 20140205634Abstract: Methods of treating a Streptococcus pneumoniae infection are described herein.Type: ApplicationFiled: February 10, 2014Publication date: July 24, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe DENOEL, Philippe Vincent HERMAND, Steve LABBE, Jan POOLMAN, Stephane RIOUX
-
Patent number: 8703148Abstract: The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine group on PNAG to form a PNAG conjugate. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising PNAG and Type 5 and/or 8 capsular polysaccharides are also described.Type: GrantFiled: March 29, 2007Date of Patent: April 22, 2014Assignee: GlaxoSmithKline Biologicals S.AInventors: Ralph Leon Biemans, Philippe Denoel, Pierre Duvivier, Tomas Maira-Litran, Jan Poolman
-
Publication number: 20140072622Abstract: The present invention relates to improved immunogenic compositions and vaccines, methods for making them and their use in medicine. In particular the invention relates to immunogenic compositions of unconjugated Streptococcus pneumoniae proteins selected from: pneumolysin and member(s) of the Polyhistidine Triad family (e.g. PhtD), which comprise adjuvants comprising QS21 and monophosphoryl lipid A (MPL), and are presented in the form of a liposome.Type: ApplicationFiled: May 15, 2012Publication date: March 13, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe Denoel, Jan Poolman, Vincent Verlant, Hugues Wallemacq
-
Patent number: 8574596Abstract: The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. The invention further provides immunogenic compositions comprising a plurality of antigens selected from at least two different categories of antigen, having different functions within Bordetella. Examples of such categories of antigen are autotransporter proteins, iron acquisition proteins, lipoproteins, adhesins and toxins/invasins.Type: GrantFiled: October 1, 2004Date of Patent: November 5, 2013Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Cindy Castado, Philippe Denoel, Fabrice Godfroid, Jan Poolman
-
Publication number: 20130171188Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.Type: ApplicationFiled: February 27, 2013Publication date: July 4, 2013Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon BIEMANS, Dominique BOUTRIAU, Carine CAPIAU, Philippe DENOEL, Pierre DUVIVIER, Jan POOLMAN
-
Patent number: 8431136Abstract: An immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates is provided, wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of all the at least two further bacterial saccharide conjugates.Type: GrantFiled: June 23, 2006Date of Patent: April 30, 2013Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 8398983Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ug.Type: GrantFiled: June 23, 2006Date of Patent: March 19, 2013Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20120328659Abstract: Immunogenic compositions and methods of treating a Streptococcus pneumoniae infection are described herein.Type: ApplicationFiled: March 8, 2011Publication date: December 27, 2012Inventors: Philippe Denoel, Philippe Vincent Hermand, Steve Labbe, Jan Poolman, Stephane Rioux
-
Publication number: 20120189654Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various (for instance 9 or more) conjugated capsular saccharides from different S. pneumoniae serotypes, wherein the composition comprises conjugated capsular saccharide 18C which is less than 80, 70, 60, 50, 40, 30, 20, 15 or 10% O-Acetylated.Type: ApplicationFiled: December 22, 2011Publication date: July 26, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Ralph Leon Biemans, Philippe Denoel, Jan Poolman, Jean Paul Prieels
-
Patent number: 8221770Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.Type: GrantFiled: October 21, 2010Date of Patent: July 17, 2012Assignee: GlaxoSmithKline Biologicals s.a.Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20120064119Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20120064120Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20120027800Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: September 29, 2011Publication date: February 2, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20110033500Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.Type: ApplicationFiled: October 21, 2010Publication date: February 10, 2011Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20100322959Abstract: The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine group on PNAG to form a PNAG conjugate. Methods of using and processes to make an immunogenic composition are also described.Type: ApplicationFiled: March 29, 2007Publication date: December 23, 2010Applicants: GLAXOSMITHKLINE BIOLOGICALS, S.A., The Brigham & Women's Hospital Inc.Inventors: Ralph Leon Biemans, Philippe Denoel, Pierre Duvivier, Tomas Maira-Litran, Jan Poolman
-
Patent number: 7838014Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and Opc, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.Type: GrantFiled: July 31, 2003Date of Patent: November 23, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20100291137Abstract: The present invention provides an isolated refolded NspA protein, and a method of preparing it.Type: ApplicationFiled: January 25, 2010Publication date: November 18, 2010Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ralph Biemans, Martine Bos, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants, Johannes Petrus Maria Tommassen
-
Patent number: 7811590Abstract: This invention relates to recombinant bacterial outer membrane proteins comprising one or more LB1(f) peptides from surface-exposed loop 3 of MOMP P5 of non-typeable H. influenzae. Polynucleotides encoding these recombinant proteins are also covered. The invention also relates to a method of isolating the recombinant proteins and a vaccine composition for use in the treatment of Haemophilus influenzae infection.Type: GrantFiled: December 20, 2007Date of Patent: October 12, 2010Assignees: The Ohio State University Research Foundation, GlaxoSmithKlineInventors: Lauren O. Bakaletz, Francois-Xavier Jacques Berthet, Philippe Denoel, Jan Poolman, Joelle Thonnard
-
Publication number: 20100021503Abstract: The present application relates to immunogenic compositions comprising Type 5 and Type 8 capsular polysaccharide or oligosaccharide from S. aureus. Methods of using and processes to make an immunogenic composition are also described.Type: ApplicationFiled: March 29, 2007Publication date: January 28, 2010Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe Denoel, Jan Poolman